Babay Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Babay Pharma
Largest movements
- Stocks and contracts +€42,302
new in 2025: €42,302
- Receivables after one year +€36,272
new in 2025: €36,272
- Receivables within one year -€21,799
no longer reported in 2025 (was €21,799)
of which Trade receivables: -€15,958
- Cash +€18,963
up €18,963 (+376.3%), from €5,040 to €24,003
mainly Net result for the year (+€75,707) and Receivables within one year (+€21,799)
- Deferred charges and accrued income +€16,550
new in 2025: €16,550
- Profit (loss) carried forward +€75,707
up €75,707 (+3949.9%), from €1,917 to €77,624
- Debts after one year -€21,384
down €21,384 (-26.5%), from €80,605 to €59,222
- Tax, wage and social debts +€16,100
up €16,100 (+267.7%), from €6,014 to €22,114
- Trade debts +€7,966
up €7,966 (+27.8%), from €28,688 to €36,654
- Other debts -€3,589
no longer reported in 2025 (was €3,589)
- Gross operating margin +€98,364
up €98,364 (+654.6%), from €15,027 to €113,391
- Taxes +€18,598
up €18,598 (+2911.0%), from €639 to €19,237
- Depreciation +€5,047
up €5,047 (+50.7%), from €9,953 to €15,000
- Financial charges +€1,553
up €1,553 (+67.8%), from €2,290 to €3,842
- Financial income +€1,488
up €1,488 (+14884500.0%), from €0 to €1,488
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €169,708 | €246,996 | +€77,289 | +45.5% |
| Fixed assets | 21/28 | €142,869 | €127,869 | -€15,000 | -10.5% |
| Intangible fixed assets | 21 | €142,869 | €127,869 | -€15,000 | -10.5% |
| Current assets | 29/58 | €26,839 | €119,128 | +€92,289 | +343.9% |
| Amounts receivable after more than one year | 29 | - | €36,272 | +€36,272 | |
| Other amounts receivable | 291 | - | €36,272 | +€36,272 | |
| Stocks and contracts in progress | 3 | - | €42,302 | +€42,302 | |
| Stocks | 30/36 | - | €42,302 | +€42,302 | |
| Amounts receivable within one year | 40/41 | €21,799 | - | -€21,799 | |
| Trade receivables | 40 | €15,958 | - | -€15,958 | |
| Other amounts receivable | 41 | €5,841 | - | -€5,841 | |
| Cash at bank and in hand | 54/58 | €5,040 | €24,003 | +€18,963 | +376.3% |
| Deferred charges and accrued income | 490/1 | - | €16,550 | +€16,550 | |
| Total equity and liabilities | 10/49 | €169,708 | €246,996 | +€77,289 | +45.5% |
| Equity | 10/15 | €31,917 | €107,624 | +€75,707 | +237.2% |
| Contributions | 10/11 | €30,000 | €30,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €1,917 | €77,624 | +€75,707 | +3949.9% |
| Amounts payable | 17/49 | €137,791 | €139,373 | +€1,581 | +1.1% |
| Amounts payable after more than one year | 17 | €80,605 | €59,222 | -€21,384 | -26.5% |
| Financial debts | 170/4 | €80,605 | €59,222 | -€21,384 | -26.5% |
| Amounts payable within one year | 42/48 | €57,186 | €80,151 | +€22,965 | +40.2% |
| Current portion of amounts payable after more than one year | 42 | €18,895 | €21,384 | +€2,489 | +13.2% |
| Trade debts | 44 | €28,688 | €36,654 | +€7,966 | +27.8% |
| Suppliers | 440/4 | €28,688 | €36,654 | +€7,966 | +27.8% |
| Taxes, remuneration and social security | 45 | €6,014 | €22,114 | +€16,100 | +267.7% |
| Taxes | 450/3 | €6,014 | €22,114 | +€16,100 | +267.7% |
| Other amounts payable | 47/48 | €3,589 | - | -€3,589 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €9,953 | €15,000 | +€5,047 | +50.7% |
| Other operating charges | 640/8 | €228 | €1,093 | +€865 | +379.0% |
| Gross operating margin | 9900 | €15,027 | €113,391 | +€98,364 | +654.6% |
| Operating profit (loss) | 9901 | €4,845 | €97,298 | +€92,453 | +1908.1% |
| Financial income | 75/76B | €0 | €1,488 | +€1,488 | +14884500.0% |
| Recurring financial income | 75 | €0 | €1,488 | +€1,488 | +14884500.0% |
| Financial charges | 65/66B | €2,290 | €3,842 | +€1,553 | +67.8% |
| Recurring financial charges | 65 | €2,290 | €3,842 | +€1,553 | +67.8% |
| Profit (loss) for the period before taxes | 9903 | €2,556 | €94,944 | +€92,389 | +3615.2% |
| Income taxes | 67/77 | €639 | €19,237 | +€18,598 | +2911.0% |
| Profit (loss) for the period | 9904 | €1,917 | €75,707 | +€73,790 | +3849.9% |
| Profit (loss) for the period to be appropriated | 9905 | €1,917 | €75,707 | +€73,790 | +3849.9% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.